Immuneering Corporation (IMRX) vs Upstream Bio, Inc. (UPB)

Immuneering Corporation and Upstream Bio, Inc. are both Biotechnology companies. Immuneering Corporation and Upstream Bio, Inc. are of similar size ($283.2M and $280.8M). Upstream Bio, Inc. grew revenue faster over the last twelve months: 16.0% against −84.8%. Immuneering Corporation has the higher net margin (0.00% vs −4,955.7%) and the higher return on invested capital (−97.1% vs −1,100.9%). Across the 16 metrics below, Upstream Bio, Inc. leads on 10 and Immuneering Corporation on 6.

Valuation

Metric IMRX UPB Biotechnology median
P/E n/m n/m 7.88
P/S 871.47 92.62 11.47
P/B 1.45 1.08 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 398.60 9.87 10.73
Earnings yield (24.36%) (54.10%) (28.84%)
Free cash flow yield (20.63%) (46.74%) (23.03%)

Profitability

Metric IMRX UPB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (5,382.65%) 0.00%
Net margin 0.00% (4,955.67%) 0.00%
Free cash flow margin 0.00% (4,317.42%) 0.00%
Return on equity (52.15%) (46.05%) (57.72%)
Return on assets (47.31%) (44.61%) (49.22%)
Return on invested capital (97.14%) (1,100.93%) 0.00%

Growth

Metric IMRX UPB Biotechnology median
Revenue growth (TTM) (84.76%) 15.98% 5.64%
EPS growth (last fiscal year) 37.75% 52.33% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IMRX UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 19.47 27.99 4.73
Net debt to EBITDA 2.94 2.11 0.96

Dividend

Metric IMRX UPB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric IMRX UPB Biotechnology median
Market cap 280.79m 283.17m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack